New drug cocktail targets Hard-to-Treat lung cancer
NCT ID NCT07463677
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests a combination of two drugs, tunlametinib and cetuximab β, in 55 people with advanced non-small cell lung cancer that has a KRAS mutation and has not responded to prior treatments. The goal is to see if the combo can shrink tumors and control the disease. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tunlametinib and Cetuximab β
- What this could lead to
- If successful, this combination could offer a new treatment option for people with a specific type of advanced lung cancer that has not responded to other therapies.
- What could go wrong
- This is an early Phase 2 trial with only 55 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Family support may be key to easing lung cancer surgery stress
- Can a drop of blood predict disease years before it strikes?
- Blood, urine, and stool may hold the key to predicting a serious side effect of lung cancer treatment
- Microwave ablation vs. radiotherapy: which Non-Surgical option works best for early lung cancer?
- Double-Targeted therapy aims to outsmart Hard-to-Treat lung cancer